RAPP (Rapport Therapeutics) Marketable Securities: $398.73 Mil (As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Marketable Securities?

Rapport Therapeutics RAPP -0.60% 14 Marketable Securities is $398.73 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Rapport Therapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $398.73 Mil.

Rapport Therapeutics's annual Marketable Securities increased from Dec. 2023 ($77.31 Mil) to Dec. 2024 ($248.48 Mil) and increased from Dec. 2024 ($248.48 Mil) to Dec. 2025 ($437.89 Mil).

Rapport Therapeutics  (NAS:RAPP) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Rapport Therapeutics Marketable Securities Related Terms

Rapport Therapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Marketable Securities Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Marketable Securities
0.00 77.31 248.48 437.89

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.78 205.38 261.67 437.89 398.73
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $398.73 Mil mean?
Rapport Therapeutics (RAPP) has a Marketable Securities of $398.73 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Marketable Securities too high?
Rapport Therapeutics' current Marketable Securities is $398.73 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Marketable Securities compare to SION and TYRA?
Rapport Therapeutics' Marketable Securities of $398.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Marketable Securities is $398.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Marketable Securities of $398.73 Mil. The current Marketable Securities is $398.73 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Marketable Securities is $398.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price